6 completed, 5 recruiting, 1 not yet recruiting, 1 terminated. 9 Phase 2, 5 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 5 | Completed 2, Recruiting 2, Terminated 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Hemangioendothelioma, Epithelioid: new trials by email Literature Review of Hemangioendothelioma, Epithelioid trials Research Report on Hemangioendothelioma, Epithelioid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma Sirolimus for injection (Albumin-bound) - Epithelioid Hemangioendothelioma | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 40 | 2026-08-01 | 2026-07-06 |
| SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma nab-Sirolimus - Epithelioid Hemangioendothelioma (EHE) | Phase 2 | Recruiting | Sarcoma Alliance for Research through Collaboration | 41 | 2026-02-24 | 2026-05-26 |
| A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors BGC515 - Mesothelioma, Epithelioid Hemangioendothelioma(EHE) | Phase 1 | Recruiting | BridGene Biosciences Inc. | 103 | 2024-06-27 | 2024-08-09 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN) Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 100 | 2023-12-01 | 2026-04-03 | |
| Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors IK-930, Osimertinib - Solid Tumors, Adult, Solid Tumor | Phase 1 | Terminated | Ikena Oncology | 67 | 2022-01-07 | 2024-11-18 |
| Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Patient with Soft Tissue Sarcoma - Soft Tissue Sarcoma, Clear Cell Sarcoma | Not applicable | Recruiting | Institut Claudius Regaud | 400 | 2021-04-26 | 2026-02-10 |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Eribulin - Angiosarcoma, Epithelioid Hemangioendothelioma | Phase 2 | Completed | Massachusetts General Hospital | 13 | 2018-01-18 | 2026-08-28 |
| Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery Questionnaire Administration, Trametinib - Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 44 | 2017-06-20 | 2024-11-26 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Durvalumab, Tremelimumab - Advanced and/or Metastatic Sarcoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 57 | 2016-08-16 | 2025-06-12 |
| Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 2 | Completed | OHSU Knight Cancer Institute | 54 | 2012-03-13 | 2021-09-27 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
Hemangiosarcoma (6) · Sarcoma (6) · Leiomyosarcoma (5) · Sarcoma, Synovial (5) · Chondrosarcoma, Extraskeletal Myxoid (4) · Histiocytoma, Malignant Fibrous (4) · Osteosarcoma (4) · Sarcoma, Alveolar Soft Part (4) · Desmoplastic Small Round Cell Tumor (3) · Fibrosarcoma (3) · Liposarcoma (3) · Neurofibrosarcoma (3) · Sarcoma, Clear Cell (3) · Chondrosarcoma (2)
Hemangioma (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms, Vascular Tissue (13) · Hemangioendothelioma (12) · Neoplasms, Connective and Soft Tissue (8) · Neoplasms, Connective Tissue (6) · Neoplasms, Muscle Tissue (6) · Neoplasms, Fibrous Tissue (5) · Histiocytoma (4) · Neoplasms, Bone Tissue (4) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Nervous System Diseases (3)
Doxorubicin (2) · Ifosfamide (2) · pazopanib (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Cisplatin (1) · Dacarbazine (1) · Epirubicin (1) · Gemcitabine (1) · HhAntag691 (1) · Injections (1) · Methotrexate (1) · Nivolumab (1) · Proton Therapy (1) · Sirolimus (1) · Sunitinib (1)
National Cancer Institute (NCI) (2) · BridGene Biosciences Inc. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Ikena Oncology (1) · Institut Claudius Regaud (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · OHSU Knight Cancer Institute (1) · Sarcoma Alliance for Research through Collaboration (1) · St. Jude Children's Research Hospital (1)
United States (9) · United Kingdom (3) · France (2) · Italy (2) · Spain (2) · Australia (1) · Austria (1) · China (1) · Denmark (1) · Germany (1) · Poland (1) · Portugal (1) · Sweden (1)
Alba Rubio (1) · Antonio Casado (1) · Caroline Germa, MD (1) · Christopher W Ryan (1) · Claudia Valverde (1) · Cristina Mata (1) · Emanuela Palmerini (1) · Giovanni Grignani (1) · Gregory Cote, MD, PhD (1) · Irene Carrasco (1)
PMID 31401903, PMID 33203665, PMID 35443056, PMID 35934010, PMID 39356980, PMID 41836677
N01CM62206 (1), P30CA008748 (1), P30CA046592 (1), U01CA069856 (1)